November 21, 2026Funding-Series BBiotech

Marrow Therapeutics Launches With $173M Series A and B to Deliver Drugs Straight to Bone Marrow

Most gene therapies for blood disorders take the bone marrow out of the patient, edit it in a lab and put it back, after chemotherapy clears room. Marrow Therapeutics wants to skip the round trip. The Watertown, Massachusetts company launched on Nov 17 with $173M across two rounds: a $120M Series B led by OrbiMed and a $53M Series A co-led by Scion Life Sciences, which founded the company, and venBio. This is a catch-up item; the launch ranked sixth on Crunchbase's weekly biggest-rounds list published inside this window. Coverage: https://www.biopharmadive.com/news/marrow-therapeutics-sickle-cell-beta-thalassemia-drug/874789/

The B round brought in a heavy crossover crowd. All Series A investors came back, joined by RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments. When names that usually buy at IPO show up before a drug reaches humans, they are buying a seat for the listing. Valuation and the split of money across programs were not disclosed. Fierce Biotech puts the Series A at $54M; most other reports say $53M. https://www.fiercebiotech.com/biotech/marrow-kicks-173m-and-preclinical-blood-disease-therapy

The technology is a Transferrin Antibody Bioconjugate platform. Bone marrow cells that make red blood cells are covered with the transferrin receptor TfR1, because they need iron. Marrow attaches its payload to an antibody that grabs that receptor, so the drug goes where blood is made. Lead candidate MAR-101 is in IND-enabling studies for sickle cell disease and beta thalassemia; BioPharma Dive notes no timeline for the clinic.

My read: $173M for a preclinical company is a bet that in vivo delivery will replace ex vivo cell editing for blood disease, which would turn a hospital procedure costing millions into something closer to an infusion. Big if, but the investor list says the market is pricing that if seriously.
← Previous
Galvanize Therapeutics Raises $130M Series D for Pulsed-Field Tumor Ablation
Next β†’
Ramon.Space Raises $124M Series B to Put Data Centers in Orbit, One Node at a Time
← Back to all articles

Comments

Loading...
>_